Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

NCT07520006 | Not Yet Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: NX-5948-203
• Study Type: interventional
• Target: 150
• Locations: 0 countries
• Sites: N/A

Brief Summary

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Conditions

B-cell Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Keywords

Chronic Lymphocytic Leukemia (CLL); Small Lymphocytic Lymphoma (SLL); Degrader; B-cell malignancy; BTKi; Bexobrutideg; Venetoclax; Obinutuzumab; Rituximab

Outcome Measures

Primary Outcomes (1)

• Number of participants with treatment-emergent adverse events

  Up to approximately 7 years

Secondary Outcomes (10)

• Objective response rate as determined by investigator

  Up to approximately 7 years

• Duration of response as determined by investigator

  Up to approximately 7 years

• Progression-free survival as determined by investigator

  Up to approximately 7 years

• Complete response rate as determined by investigator

  Up to approximately 7 years

• Time to response as determined by investigator

  Up to approximately 7 years

Study Arms (3)

NX-5948 + venetoclax

EXPERIMENTAL

Drug: NX-5948; Drug: venetoclax

NX-5948 + venetoclax + rituximab

EXPERIMENTAL

Drug: NX-5948; Drug: venetoclax; Drug: rituximab

NX-5948 + venetoclax + obinutuzumab

EXPERIMENTAL

Drug: NX-5948; Drug: venetoclax; Drug: obinutuzumab

Interventions

rituximab DRUG

Administered as an intravenous (IV) infusion per prescribing information

NX-5948 + venetoclax + rituximab

NX-5948 DRUG

Administered orally once daily as a capsule

Also known as: bexobrutideg

NX-5948 + venetoclax; NX-5948 + venetoclax + obinutuzumab; NX-5948 + venetoclax + rituximab

venetoclax DRUG

Administered orally once daily as a tablet per prescribing information

NX-5948 + venetoclax; NX-5948 + venetoclax + obinutuzumab; NX-5948 + venetoclax + rituximab

obinutuzumab DRUG

Administered as an IV infusion per prescribing information

NX-5948 + venetoclax + obinutuzumab

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
• Adequate organ and bone marrow function
• Measurable disease by computed tomography (CT) per iwCLL
• For R/R CLL/SLL, prior therapy must include treatment with a Bruton tyrosine kinase inhibitor (BTKi)
• For 1L CLL/SLL, confirmed previously untreated CLL/SLL with a clinical indication for systemic treatment that meets iwCLL criteria
• Must sign an informed consent form indicating understanding of the study purpose and procedures and willingness to participate

You may not qualify if:

• Known or suspected prolymphocytic leukemia or Richter's transformation at any time preceding enrollment
• Investigational agent or anticancer therapy within 5 half-lives or 14 days (whichever is shorter) prior to planned start of study treatment
• Radiotherapy within 2 weeks of the first dose of study drug except for focal palliative radiation
• Use of systemic corticosteroids (\>20 mg/day prednisone or equivalent) within the 7 days prior to initiation of study treatment excepting those used as prophylaxis for radiodiagnostic contrast
• Previously treated with a BTK degrader
• Previously treated with a BCL-2 inhibitor (BCL-2i) unless eligible for retreatment
• Known central nervous system (CNS) lymphoma or leukemia
• Myocardial infarction, unstable angina, unstable symptomatic ischemic heart disease, placement of a coronary arterial stent, or any other significant cardiac condition within 6 months of planned start of study treatment
• Thromboembolic events, stroke, or intracranial hemorrhage within 6 months of planned start of study treatment

Sponsors & Collaborators

• Nurix Therapeutics, Inc.: lead

MeSH Terms

Conditions

Lymphoma, B-Cell; Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

venetoclax; Rituximab; obinutuzumab

Condition Hierarchy (Ancestors)

Lymphoma, Non-Hodgkin; Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases; Leukemia, B-Cell; Leukemia, Lymphoid; Leukemia; Hematologic Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Study Director

  Nurix Therapeutics, Inc.

  STUDY DIRECTOR

Central Study Contacts

Additional Site Contact Information

CONTACT

415-417-3418; clinicaltrials@nurixtx.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2026
• First Posted: April 9, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2033
• Study Completion (Estimated): May 1, 2033
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share